secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001664710-25-000071
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros discontinues cibotercept development, prioritizes KER-065; CEO becomes President, COO departs
--------------------------------------------------------------------------------

- Discontinuing all internal development of cibotercept (KER-012) after PAH trial termination.
- Exclusively prioritizing KER-065 for Duchenne muscular dystrophy; Phase 2 expected Q1 2026.
- CEO Jasbir Seehra adds President role effective Aug 18, 2025; steps down as Board Chair.
- Jean-Jacques Bienaimé appointed Chair of the Board, effective Aug 18, 2025.
- COO Christopher Rovaldi to depart Aug 18; Lorena Lerner promoted to CSO; SVP roles eliminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000071/0001664710-25-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000071/kros-20250806.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer